KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pacific Biosciences Of California (PACB) Receivables - Other (2011 - 2017)

Pacific Biosciences Of California's quarterly Receivables - Other came in at $755000.0 in Q3 2017, little changed quarter-over-quarter from $755000.0 in Q2 2017.

Pacific Biosciences Of California has reported Receivables - Other for 6 years, with the latest figure at $755000.0 in Q3 2017.

  • For the quarter ending Q3 2017, Receivables - Other changed N/A year-over-year to $755000.0; the trailing twelve-month figure through Sep 2017 stood at $755000.0 (changed N/A YoY), and the FY2016 full-year result was $5.0 million, down 50.0% from the prior year.
  • Receivables - Other for Q3 2017 stood at $755000.0, roughly flat from $755000.0 in the prior quarter.
  • The five-year high for Receivables - Other was $10.0 million in Q4 2015, with the low at $3000.0 in Q4 2013.
  • Average Receivables - Other over 4 years is $3.4 million, with a median of $2.4 million recorded in 2017.
  • Year-over-year, Receivables - Other sank 99.63% in 2013 and sank 50.0% in 2016.
  • Tracing PACB's Receivables - Other over 4 years: stood at $3000.0 in 2013, then soared by 333233.33% to $10.0 million in 2015, then slumped by 50.0% to $5.0 million in 2016, then sank by 84.9% to $755000.0 in 2017.
  • The last three Receivables - Other figures came in at $755000.0 (Q3 2017), $755000.0 (Q2 2017), and $2.4 million (Q1 2017), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Pacific Biosciences Of California 481.66 Mn 205.70 Mn 12.84 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2017 755,000.00
Sep 30, 2017 755,000.00
Jun 30, 2017 755,000.00
Jun 30, 2017 755,000.00
Mar 31, 2017 2.44 Mn
Mar 31, 2017 2.44 Mn
Dec 31, 2016 5.00 Mn
Dec 31, 2016 5.00 Mn
Jun 30, 2016 5.00 Mn
Jun 30, 2016 5.00 Mn
Dec 31, 2015 10.00 Mn
Dec 31, 2015 10.00 Mn
Dec 31, 2013 3,000.00
Dec 31, 2013 3,000.00
Dec 31, 2012 814,000.00
Dec 31, 2012 814,000.00
Dec 31, 2011 17,000.00
Dec 31, 2011 17,000.00